Single dose oral pharmacokinetic profile rubraxanthone in mice

Meri Susanti; Riski Darmianti; Yahdiana Harahap; Afrizal Itam; Dachriyanus Hamidi

doi:10.1016/j.heliyon.2022.e09104

Single dose oral pharmacokinetic profile rubraxanthone in mice

Heliyon. 2022 Mar 14;8(3):e09104. doi: 10.1016/j.heliyon.2022.e09104. eCollection 2022 Mar.

Authors

Meri Susanti¹, Riski Darmianti¹, Yahdiana Harahap², Afrizal Itam³, Dachriyanus Hamidi¹

Affiliations

¹ Faculty of Pharmacy, Universitas Andalas, Padang, West Sumatra, 25163, Indonesia.
² Faculty of Pharmacy, Universitas Indonesia, Depok, West Java, Indonesia.
³ Department of Chemistry, FMIPA, Universitas Andalas, Padang, West Sumatra, 25163, Indonesia.

Abstract

Rubraxanthone is a main active constituent of kandis (Garcinia cowa Roxb), has showed many biological activity including antimicrobial, anti hypercholesterolemic, antiplatelet, antioxidant, cytotoxic, and anti-inflammatory properties. To the best of our knowledge, no reports on the pharmacokinetics (PK) of this rubraxanthone have been published. The PK of rubraxanthone in mice was examined after a single oral dose of 700 mg/kg rubraxanthone suspension in virgin coconut oil. Plasma samples were collected at different time points and further analyzed using validated chromatographic method. Pharmacokinetic parameters were calculated from observed plasma concentration-time profile. The maximum concentration of rubraxanthone in plasma was discovered in 1.5 h. The peak plasma concentration (C_max) was 4.267 μg/mL, and the area under the curve (AUCt0-t $\infty$ ) was 560.99 μg h/L, with a 6.72-hour terminal half-life (T_1/2). The volume of distribution (Vd/F) was 1200.19 mL/kg and 1123.88 mL/h/kg clearance (Cl/F).

Keywords: Bioanalysis; Pharmacokinetic; Rubraxanthone; UHPLC; Validation.